Internship
Biotech company focused on gene editing
No salary listed
No H1B Sponsorship
Belmont, MA, USA
We are currently not considering co-op candidates outside of the local Boston/Cambridge area.
Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This method can identify and fix faulty DNA segments, helping to restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, it emphasizes collaboration with research institutions and pharmaceutical companies to advance its technology and bring it to market through licensing agreements and partnerships. The leadership team, including experienced professionals like Chief Technical Officer Ann L. Lee, is dedicated to enhancing the company's technological capabilities and scaling operations.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Prime Medicine has been developing its Prime Editing technology, a novel genetic editing approach, which recently gained further credibility through validation by a similar method from Beam Therapeutics.
Prime Medicine Inc. has announced its new preclinical program for the treatment of α1-antitrypsin deficiency (AATD).
Prime Medicine (PRME) has secured $244.6 million to advance its genetic therapies using its Prime Editing platform, which allows precise DNA modifications without double-stranded breaks. The company is progressing its pipeline, including therapies for chronic granulomatous disease and Wilson’s disease. A $110 million upfront payment from a partnership with Bristol Myers Squibb supports its strategic growth, with potential milestone payments exceeding $3.5 billion.
Verition Fund Management LLC makes new $149,000 Investment in Prime Medicine, Inc. (NYSE:PRME).
Prime Medicine plans to aggressively prosecute patent infringement.